top of page
  • Completed

NCT04754100: Phase 1 - AGENT-797 in Participants With Relapsed/Refractory Multiple Myeloma

Updated: Feb 10

  • NCT04754100: Phase 1 - AGENT-797 in Participants With Relapsed/Refractory Multiple Myeloma


AGENT-797

This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in patients with relapsed or refractory multiple myeloma.


Sponsor

Agenus Inc. ( MiNK Therapeutics )

 

ClinicalTrials.gov Identifier: NCT04754100


Official Title: A PHASE I OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND PRELIMINARY CLINICAL ACTIVITY OF ALLOGENEIC INVARIANT NATURAL KILLER (INKT) NON-TRANSDUCED CELLS (AGENT-797) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA


First Posted : February 15, 2021


Click here for details on ClinicalTrials.gov

 

Allogeneic Invariant Natural Killer T-cells agenT-797

Allogeneic Invariant Natural Killer T-cells agenT-797 (Code C178501)

AGENT 797

AgenT-797

AGENT-797

agenT797

Allogeneic iNKT agenT-797

 

- Kentucky: Norton Cancer Institute Louisville

- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

 

Drug: agenT-797

 

Locations

United States, Kentucky

United States, Massachusetts

Comments


Commenting has been turned off.
Posts Archive
bottom of page